Q3 results posts ups and downs in India pharma sector
Indian pharma companies have posted their third quarter results. Express Pharma highlights the results
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
New rules on compensation to make clinical trials in India ‘virtually impossible’: ISCR
Notification goes against consensus reached in stakeholder meetings on two crucial criteria, alleges ISCR
Medicines Compendium expands global reach through new expert committees, enhanced website
Experts from Argentina, Bangladesh, Brazil, China, Korea, Pakistan and the UK reflect growth of the MC
Marck Biosciences takes private equity route with Tata Capital
To invest Rs 80 crores in new project
Glenmark initiates IND enabling studies of novel monoclonal antibody targeting OX40
GBR 830 is the first antagonistic antibody targeting OX40 and is a potential Global First-in-class molecule
M&A activity in pharma sector focuses on expanding product offerings
January 2013 registers slight increase in volume terms and decrease in value terms
STEM-2013 redefines stem cell research in India
Researchers from France, Argentina and Brazil provided useful inputs about the regulatory scenario
GIPC-2013 sees congregation of IP experts
More than 300 speakers from 30 countries participated in the event
Bangalore INDIA BIO 2013 ends on a promising note
110 speakers, 878 delegates, over 500 organisations and 100 exhibitors from various verticals of life sciences industry…
High Potent Drugs-2013 debates regulatory complexities
Conference in Mumbai brought together international and domestic experts who discussed high potent drugs related R&D and…